Visus Therapeutics, a Seattle-based startup developing a presbyopia-correcting eye drop, raised $36 million. Johnson & Johnson Innovation, the venture capital arm of J&J, invested in the Series A round, in addition to RTW Investments, LP, Wille AG, and existing backers.
The companyҳ lead asset, BRIMOCHOL, is a once-daily eye drop that aims to treatpresbyopia, a vision condition caused by aging that can make tasks such as reading difficult. It affects about 123 million adults in the U.S., according to the company. Existing treatments include glasses, contact lenses, or surgery.
Founded in 2019, Visus is led by CEOBen
Title: Visus Therapeutics raises $36M from J&Jҳ VC arm, others to develop eye drop that treats presbyopia
Sourced From: contacted.org/visus-therapeutics-raises-36m-from-jjs-vc-arm-others-to-develop-eye-drop-that-treats-presbyopia/
Published Date: Wed, 10 Mar 2021 16:15:37 +0000